Menstrual Cycle Phase Linked to COVID-19 Vaccine Side Effects and Breakthrough Infection Timing
核心洞察
A study of 1,474 period-tracking app users found that individuals vaccinated during the follicular phase had 35% higher odds of reporting side effects compared to those vaccinated in the luteal phase.
Younger participants aged 18–24 showed a stronger follicular-phase association with side effects (OR: 2.18, 95% CI: 1.24–3.84), likely driven by lower luteal-phase reporting.
Exploratory data showed median time to breakthrough infection was 35 days longer for the follicular group (200 vs. 165 days, p = 0.05), though this finding was underpowered.
A new app-based study published in npj Women's Health suggests that the phase of the menstrual cycle at the time of COVID-19 (搜索) vaccination may influence both self-reported side effects and, in exploratory analyses, the timing of subsequent breakthrough infections. The research, conducted in collaboration with the period-tracking application Clue, analyzed data from 1,474 individuals across the US, UK, Canada, and Australia.
The findings showed that 75.9% of participants vaccinated during the estrogen-dominant follicular phase reported side effects, compared to 70.3% of those vaccinated during the progesterone-dominant luteal phase. After adjusting for age, body mass index, smoking status, and pre-existing medical conditions, follicular-phase vaccination was associated with 35% higher odds of self-reported side effects (OR = 1.35).
"For too long, the menstrual cycle has been treated as background noise in health research," said Poppy Cooper at the London School of Hygiene & Tropical Medicine. "This work is part of a growing shift in that thinking and a recognition that the menstrual cycle has impacts beyond reproductive health."
Age-Stratified Effects and Severity Findings
The association between cycle phase and side effects was particularly pronounced among younger participants. Those aged 18 to 24 showed a markedly stronger follicular-phase association, with an odds ratio of 2.18 (95% CI: 1.24–3.84), a pattern the researchers suggest may be driven by lower side-effect reporting in the luteal phase among this age group.
Notably, the regression models did not identify a statistically significant association between menstrual phase timing and side effect severity (OR = 1.21), nor between phase timing and the total number of side effects reported (IRR = 1.03).
Exploratory Infection Timing Data
The study also examined self-reported breakthrough COVID-19 (搜索) infections over a 67- to 372-day window post-vaccination. The median time to breakthrough infection was 35 days longer for those vaccinated during the follicular phase compared to the luteal phase (200 days vs. 165 days, p = 0.05).
However, only 82 participants reported breakthrough infections, and a subsequent Cox proportional hazards model was found to be statistically underpowered at 29%. The authors therefore interpreted the infection finding as descriptive and hypothesis-generating rather than confirmatory.
Biological Rationale
The hypothesis underlying the study draws on decades of research establishing that sex steroid hormones fluctuate significantly throughout the menstrual cycle. Estradiol generally acts as an immune enhancer in a context-dependent manner, whereas progesterone tends to act as a relative immune suppressant. Because these hormones bind directly to receptors on immune cells, scientists hypothesize that the estrogen-dominant follicular phase might amplify vaccine reactogenicity and potentially influence immunogenicity.
"Progesterone's job, biologically, is to prepare the body to tolerate a potential pregnancy," said Julia Craggs, a doctor specializing in women's health. "One way it does that is by turning down some of the more aggressive parts of the immune system, like T cell activity. That isn't necessarily what you want at the precise moment you are trying to train the immune system to recognise a vaccine antigen."
Study Design and Limitations
The study classified participants based on a calendar estimation of their menstrual phase at the time of vaccination. The luteal phase was defined, per International Federation of Gynecology and Obstetrics (FIGO) criteria, as the 14 days before a participant's next documented menstruation. The final analytical cohort of 1,474 was drawn from more than 13,000 initial respondents, with exclusions for those using hormonal contraceptives, those with recent pregnancies, those with irregular cycles, and those with insufficient cycle tracking data.
The authors acknowledge several limitations, including exclusive reliance on calendar-based estimates rather than direct hormonal biomarkers, self-reported vaccine and infection outcomes, possible recall bias, and a self-selected app-user sample. The observational nature of the study does not establish causation.
"This study treats the menstrual cycle as a variable that matters rather than a confounding variable to simply control away," said Craggs. "We may be sitting on a significant source of unexplained variation in how women respond to treatment and we have simply never looked in that direction."
Cooper stressed that vaccines remain important for protecting against infections regardless of cycle timing, but added: "I'd love to see the same question asked across other vaccines and medical interventions." Future work will need to determine whether the side-effect pattern reflects immune activation, differences in pain perception, or misattribution of menstrual-cycle symptoms.